All Title Author
Keywords Abstract

PLOS ONE  2014 

HIV Screening among TB Patients and Co-Trimoxazole Preventive Therapy for TB/HIV Patients in Addis Ababa: Facility Based Descriptive Study

DOI: 10.1371/journal.pone.0086614

Full-Text   Cite this paper   Add to My Lib


Background Collaborative TB/HIV management is essential to ensure that HIV positive TB patients are identified and treated appropriately, and to prevent tuberculosis (TB) in HIV positive patients. The purpose of this study was to assess HIV case finding among TB patients and Co-trimoxazole Preventive Therapy (CPT) for HIV/TB patients in Addis Ababa. Methods A descriptive cross-sectional, facility-based survey was conducted between June and July 2011. Data was collected by interviewing 834 TB patients from ten health facilities in Addis Ababa. Both descriptive and inferential statistics were used to summarize and analyze findings. Results The proportion of TB patients who (self reported) were offered for HIV test, tested for HIV and tested HIV positive during their anti-TB treatment follow-up were; 87.4%, 69.4% and 20.2%; respectively. Eighty seven HIV positive patients were identified, who knew their status before diagnosed for the current TB disease, bringing the cumulative prevalence of HIV among TB patients to 24.5%. Hence, the proportion of TB patients who knew their HIV status becomes 79.9%. The study revealed that 43.6% of those newly identified HIV positives during anti-TB treatment follow-up were actually treated with CPT. However, the commutative proportion of HIV positive TB patients who were ever treated with CPT was 54.4%; both those treated before the current TB disease and during anti-TB treatment follow-up. Conclusions HIV case finding among TB patients and provision of CPT for TB/HIV co-infected patients needs boosting. Hence, routine offering of HIV test and provision of CPT for PLHIV should be strengthened in-line with the national guidelines.


[1]  United Nations Program for HIV/AIDS (UNAIDS) (2011) Global report: UNAIDS report on the global AIDS epidemic 2011. Geneva, Switzerland: United Nations Program for HIV/AIDS (UNAIDS).
[2]  World Health Organization (2011) Global tuberculosis report 2011. Geneva, Switzerland: World Health Organization (WHO).
[3]  World Health Organization (2012) WHO policy on collaborative TB/HIV activities: Guidelines for national programs and other stakeholders. Geneva, Switzerland: World Health Organization (WHO).
[4]  World Health Organization (2007) Guidance on Provider-Initiated HIV Testing and Counseling in Health Facilities. Geneva, Switzerland: World Health Organization (WHO).
[5]  World Health Organization (2006) Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva, Switzerland: World Health Organization (WHO).
[6]  Federal HIV/AIDS Prevention and Control Office (FHAPCO) (2007) Guidelines for HIV Counseling and Testing in Ethiopia. Addis Ababa, Ethiopia: Federal HIV/AIDS Prevention and Control Office (FHAPCO).
[7]  Federal Ministry of Health of Ethiopia (2007) Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia: Federal Ministry of Health of Ethiopia (FMoH).
[8]  Andrew JN, Peter M, Chifumbe C, Alwyn M, Janet HD, et al. (2008) Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomized clinical trial. BMJ 337: a257. doi: 10.1136/bmj.a257
[9]  Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, et al. (1999) Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d’Ivoire: a randomised controlled trial. The Lancet 353(9163): 1469–1475. doi: 10.1016/s0140-6736(99)03465-0
[10]  World Health Organization (WHO) (2007) TB/HIV Monitoring and Advocacy Project Interview Tool. Geneva, Switzerland. Available: Accessed 2012 Jun 9.
[11]  World Health Organization (2009) Global tuberculosis control: surveillance, planning financing. Geneva, Switzerland: World Health Organization (WHO).
[12]  Anthony DH, Rony Z, Elizabeth LC, Stephen DL, Ezio TS, et al. (2010) The HIV-associated tuberculosis epidemic–when will we act? The Lancet 375(9729): 1906–1919. doi: 10.1016/s0140-6736(10)60409-6
[13]  Kong DG, Watt JP, Marks S, Flood J (2013) HIV status determination among tuberculosis patients from California during 2008. J Public Health Manag Pract 19(2): 169–177. doi: 10.1097/phh.0b013e3182550a83
[14]  Klein PW, Harris TG, Leone PA, Pettifor AE (2013) HIV Testing of Tuberculoss Patients by Public and Private Providers in New York City. J Community Health [Epub ahead of print].
[15]  Yadeta D, Alemseged F, Biadgilign S (2013) Provider-initiated HIV testing and counseling among tuberculosis patients in a hospital in the Oromia region of Ethiopia. J Infect Public Health 6(3): 222–229. doi: 10.1016/j.jiph.2013.01.002
[16]  Bipra B, Sudipto B, Ajay MV, Eleanor SC, Vineet KC, et al. (2013) What Are the Reasons for Poor Uptake of HIV Testing among Patients with TB in an Eastern India District? PLoS One 8(3): e55229. doi: 10.1371/journal.pone.0055229
[17]  Addis Ababa City Administration Health Bureau (AACAHB) (2010) Annualized City Administration Health Bureau Activity Report for 2009. Addis Ababa, Ethiopia: Addis Ababa City Administration Health Bureau (AACAHB).
[18]  World Health Organization (WHO) (2009) A guide to monitoring and evaluation for collaborative TB/HIV activities –2009 revision. Geneva, Switzerland: World Health Organization (WHO).
[19]  Deribew A, Negussu N, Melaku Z, Deribe K (2011) Investigation outcomes of tuberculosis suspects in the health centers of Addis Ababa, Ethiopia. PLoS One 6: e18614. doi: 10.1371/journal.pone.0018614
[20]  Srikantiah P, Lin R, Walusimbi M, Okwera A, Luzze H, et al. (2007) Elevated HIV sero-prevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. Int J Tuberc Lung Dis 11: 168–174.
[21]  Adjei AA, Adiku TK, Ayeh-Kumi PF, Hesse IF (2006) Prevalence of human immunodeficiency virus infection among tuberculosis suspect patients in Accra, Ghana. West Afr J Med 25: 38–41. doi: 10.4314/wajm.v25i1.28243
[22]  Odhiambo J, Kizito W, Njoroge A, Wambua N, Nganga L (2008) Provider-initiated HIV testing and counseling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis 11: 63–68.
[23]  Munthali L, Mwaungulu JN, Munthali K, Bowie C, Crampin AC (2006) Using tuberculosis suspects to identify patients eligible for antiretroviral treatment. Int J Tuberc Lung Dis 10: 199–202.
[24]  Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, et al. (2007) Effect of Co-trimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 21: 77–84. doi: 10.1097/qad.0b013e3280114ed7
[25]  Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, et al. (2007) Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering Co-trimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 46: 56–61. doi: 10.1097/qai.0b013e3181378ed2
[26]  World Health Organization (WHO) (2006) The global plan to stop TB, 2006–2015: Action for life: Towards a world free of tuberculosis. Geneva, Switzerland: World Health Organization (WHO).
[27]  Alemayehu YK, Bushen OY, Muluneh AT (2009) Evaluation of HIV/AIDS clinical care quality: the case of a referral hospital in North West Ethiopia. Int J Qual Health Care 21(5): 356–362. doi: 10.1093/intqhc/mzp030
[28]  Kassa A, Jerene D, Assefa Y, Teka A, Assefa A, Deribew A (2012) Evaluation of collaborative TB/HIV activities in a general hospital in Addis Ababa, Ethiopia. BMC Res Notes, 5 67 doci:10.1186/1756-0500-67.
[29]  Kapata N, Chanda-Kapata P, Grobusch MP, O’Grady J, Schwank S, et al. (2011) Scale-up of TB and HIV program collaborative activities in Zambia - a 10-year review. Trop Med Int Health 17(6): 760–766. doi: 10.1111/j.1365-3156.2012.02981.x


comments powered by Disqus